Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

Revolutionary Hemophilia gene therapy at Sheba: Coming Closer to a Cure for Hemophilia

Researchers at Sheba Medical Center are advancing rapidly towards a cure for hemophilia, a bleeding disorder that prevents normal blood clotting. At present, more than 400,000 individuals suffer from hemophilia around the globe. The revolutionary hemophilia gene therapy can only bring new hope to patients.

Using breakthrough gene therapy to eradicate hemophilia with a single dose of treatment, Sheba is one of the first hospitals worldwide to conduct this Phase III clinical trial on humans. Currently, six hemophilia patients are participating in Sheba’s clinical trial and receiving the treatment. The results of the trial will be known within two months.

The innovative, experimental hemophilia gene therapy contains the common human “adenovirus,” which was developed by a bio-pharma company in the USA. The virus is used to deliver a healthy copy of a gene that compensates for the defective gene responsible for the excessive bleeding. Ultimately, the goal is to cure hemophilia with just one dose of this treatment.

Prof. Gili Kenet researched Revolutionary Hemophilia Gene Therapy
Prof. Gili Kenet, director of the National Hemophilia Center and Institute of Thrombosis & Hemostasis

Prof. Gili Kenet, pediatric hematologist and director of the National Hemophilia Center and Institute of Thrombosis & Hemostasis at Sheba, and a professor of hematology at Sackler Medical School, Tel Aviv University, is leading this study.

“We have worked with this particular bio-pharma company on a variety of treatments for hemophilia because they value our first-class research facilities and our dedication to finding ways to help our patients,” said Prof. Kenet. “I am cautiously optimistic that this new type of gene therapy will finally help eradicate this disease.”

Currently, treatment for hemophilia entails receiving infusions every few days with medicine to promote blood clotting. One participant in the clinical trial, a 23-year old male patient, has been undergoing infusions for hemophilia at Sheba since birth. He shares, “Though I like coming to Sheba for treatments over the years because of Prof. Kenet’s professionalism and dedication, which includes her entire doting staff, I would love to get rid of this disease – so I can go ahead and live a normal life.”

Elisheva Fisher: Nurturing Hope and Strength at Sheba’s Safra Children’s Hospital
Elisheva navigates her responsibilities with a profound sense of purpose, creating an environment where medical care is interwoven with emotional support. Her presence is a…
Read More
An Inspirational Model for Pediatric Psychiatric Care in Israel and Beyond
In an era where mental health has earned critical attention, finding compassionate and effective treatment for pediatric psychiatric concerns has become an objective for many…
Read More
Sheba’s Subterranean Refuge: Protecting the Pediatric ICU 
In the face of adversity, Sheba emerges as an epitome of resilience, responding to the relentless rocket attacks and ensuring the safety of young patients…
Read More